Windlas Biotech has informed that Board of Directors at its Meeting held on Tuesday, August 13, 2024, approved the Unaudited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2024. In this regard it has enclosed the following: i. Un-audited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2024. ii. Limited Review Report of the Auditors on Standalone and Consolidated Financial Results for the Quarter ended June 30, 2024. The meeting of the Board of Directors commenced at 12.45 pm and concluded at 2.00 pm.
The above information is a part of company’s filings submitted to BSE.